WO2004005883A3 - Secreted and cytoplasmic tumor endothelial markers - Google Patents

Secreted and cytoplasmic tumor endothelial markers Download PDF

Info

Publication number
WO2004005883A3
WO2004005883A3 PCT/US2003/016250 US0316250W WO2004005883A3 WO 2004005883 A3 WO2004005883 A3 WO 2004005883A3 US 0316250 W US0316250 W US 0316250W WO 2004005883 A3 WO2004005883 A3 WO 2004005883A3
Authority
WO
WIPO (PCT)
Prior art keywords
endothelium
genes
normal
tumor
transcripts
Prior art date
Application number
PCT/US2003/016250
Other languages
French (fr)
Other versions
WO2004005883A2 (en
Inventor
Croix Brad St
Kenneth W Kinzler
Bert Vogelstein
Original Assignee
Univ Johns Hopkins
Croix Brad St
Kenneth W Kinzler
Bert Vogelstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Croix Brad St, Kenneth W Kinzler, Bert Vogelstein filed Critical Univ Johns Hopkins
Priority to AU2003281325A priority Critical patent/AU2003281325A1/en
Priority to US10/519,805 priority patent/US20090233270A9/en
Publication of WO2004005883A2 publication Critical patent/WO2004005883A2/en
Publication of WO2004005883A3 publication Critical patent/WO2004005883A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.
PCT/US2003/016250 2000-08-02 2003-07-02 Secreted and cytoplasmic tumor endothelial markers WO2004005883A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003281325A AU2003281325A1 (en) 2002-07-02 2003-07-02 Secreted and cytoplasmic tumor endothelial markers
US10/519,805 US20090233270A9 (en) 2000-08-02 2003-07-02 Secreted and cytoplasmic tumor endothelial markers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39302302P 2002-07-02 2002-07-02
US60/393,023 2002-07-02
US45896403P 2003-04-01 2003-04-01
US60/458,964 2003-04-01

Publications (2)

Publication Number Publication Date
WO2004005883A2 WO2004005883A2 (en) 2004-01-15
WO2004005883A3 true WO2004005883A3 (en) 2006-07-27

Family

ID=30118367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016250 WO2004005883A2 (en) 2000-08-02 2003-07-02 Secreted and cytoplasmic tumor endothelial markers

Country Status (2)

Country Link
AU (1) AU2003281325A1 (en)
WO (1) WO2004005883A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513251C (en) 2003-01-14 2013-03-19 Dana-Farber Cancer Institute Cancer therapy sensitizer
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP1813943B1 (en) * 2004-10-19 2009-09-23 Kumamoto University Novel diagnostic kit for malignant melanoma
AU2006237613A1 (en) 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
US20100028256A1 (en) 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP2407175A1 (en) * 2007-09-07 2012-01-18 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
US8541544B2 (en) * 2008-10-27 2013-09-24 Dainippon Sumitomo Pharma Co., Ltd. Molecular marker for cancer stem cell
CN101708328A (en) * 2009-11-06 2010-05-19 上海市免疫学研究所 Pharmaceutical application of CYR61 protein
MX2013014065A (en) 2011-06-02 2014-06-23 Almac Diagnostics Ltd Molecular diagnostic test for cancer.
EP2925885B1 (en) 2012-12-03 2020-02-05 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
KR101535717B1 (en) * 2013-09-11 2015-07-09 연세대학교 산학협력단 Composition for pancreatic cancer diagnosis comprising complememt factor i-specific binding polypeptide or antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARSON-WALTER ET AL.: "Cell Surface Tumor Endothelial Markers Are Conserved in Mice and Humans", CANCER RESEARCH, vol. 61, 15 September 2001 (2001-09-15), pages 6649 - 6655 *
NOVATCHKOVA ET AL.: "Can molecular mechanisms of biological processes be extracted from expression profiles?", BIOESSAYS, vol. 23, 2001, pages 1159 - 1175 *
ST. CROIX ET AL.: "Genes Expressed in Human Tumor Endothelium", SCIENCE, 18 August 2000 (2000-08-18), pages 1197 - 1202, XP002222041, DOI: doi:10.1126/science.289.5482.1197 *
WANG ET AL.: "Identification of Tumor Angiogenesis-Related Genes by Subtractive Hybridization", MICROVASCULAR RESEARCH, vol. 59, 2000, pages 394 - 397, XP002372830, DOI: doi:10.1006/mvre.2000.2242 *

Also Published As

Publication number Publication date
WO2004005883A2 (en) 2004-01-15
AU2003281325A1 (en) 2004-01-23
AU2003281325A8 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
WO2002010217A3 (en) Endothelial cell expression patterns
WO2004001004A3 (en) Membrane associated tumor endothelium markers
WO2004016758A3 (en) Brain endothelial cell expression patterns
WO2004091383A3 (en) Breast endothelial cell expression patterns
WO2004005883A3 (en) Secreted and cytoplasmic tumor endothelial markers
WO2002083874A3 (en) Endothelial cell expression patterns
WO1998053319A3 (en) Gene expression profiles in normal and cancer cells
WO2000022130A3 (en) Metastatic breast and colon cancer regulated genes
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2002044331A3 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
EP2505668A3 (en) MicroRNA-based methods for the diagnosis of colon, lung, and pancreatic cancer
WO2006047482A3 (en) Method for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts using cyst aspirate
AU2014899A (en) Metastatic breast and colon cancer regulated genes
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
WO2006017150A3 (en) Identification of markers in lung and breast cancer
WO2007009755A8 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2006015742A3 (en) Tumor marker for use in the diagnosis of colorectal carcinomas and/or metastases originating therefrom
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors
WO2001030964A3 (en) Anti-cancer nucleic acid and protein targets
WO2003032813A3 (en) Methods for the treatment of carcinoma
EP1367138A3 (en) Markers for breast cancer prognosis
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
WO2003031930A3 (en) A phosphatase associated with metastasis
WO2000050595A3 (en) Nucleic acid molecules associated with melanoma and thyroid tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10519805

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10519805

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10519805

Country of ref document: US